• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus

by Jasmine Pennic 03/18/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
 Sequel Med Tech's twiist AID System to Integrate Abbott's FreeStyle Libre 3 Plus

What You Should Know: 

– Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device.

– The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is designed to provide unprecedented accuracy and personalized insulin delivery. Notably, it’s the first insulin delivery system to directly measure the volume of insulin delivered with each micro-dose.

Addressing Barriers to AID System Adoption:

Despite the proven benefits of AID systems and guidelines from the American Diabetes Association recommending their use for all individuals with T1D, only about 60% of those eligible currently utilize them. Concerns about affordability, limited personalization, and trust in these systems contribute to this gap.

Key Features and Benefits

  • iiSure Technology: This proprietary technology includes four checkpoints for accurate insulin delivery and alerts users to blockages up to nine times faster than competing AID systems.
  • Personalized Dosing: Cleared for individuals aged six and up with T1D, the twiist system offers tailored dosing to meet individual needs.
  • Direct Insulin Measurement: The system directly measures the volume of insulin delivered with each micro-dose.
  • FreeStyle Libre 3 Plus Integration: Seamless compatibility with Abbott’s advanced CGM sensor.
  • Affordability and Flexibility: The twiist AID System is designed to be accessible, with a $0 first month and no more than $50 per month thereafter for eligible individuals with commercial insurance. This accessibility also means that patients can try the system without the typical long-term commitment.

“We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology2 as our first CGM partner, marking a significant milestone as we bring our innovative AID system to market,” said Sequel CEO and Co-Founder Alan Lotvin, MD. “This collaboration highlights our commitment to making advanced diabetes management more accessible and flexible for people living with diabetes. Abbott’s FreeStyle Libre technology, known for its user-friendly design and broad accessibility, complements our innovative system.”

*To be eligible for the twiist Savings Program, participants must have commercial insurance and not be enrolled in programs that pay for prescriptions in whole or in part by Medicare, Medicaid or any other federal or state programs. It is only valid in the United States, and not valid for cash-paying participants, in Puerto Rico or other U.S. Territories, or where prohibited by law. The pay no more than $50 offer is applicable to most participants on commercial insurance, based on copay and coinsurance averages across all tiered cost sharing plan designs, but may not be applicable to participants on high-deductible plans who have not yet reached their deductible. Max benefit per month for covered claims is $200.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Continuous Glucose Monitoring (CGM), Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |